A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer

Stopped The study termination is based on Sponsor decision and is not related to any safety, efficacy or quality concerns.

Conditions

• Advanced/Recurrent Ovarian Cancer

Interventions

• DRUG: Saruparib

Sponsor

AstraZeneca

Collaborators

• [object Object]